跳至主要内容
临床试验/NCT00169702
NCT00169702已完成不适用

The Effect of a Weight Management Program to Prevent Weight Gain and Metabolic Abnormalities During Treatment With the Atypical Neuroleptic Olanzapine: A Randomised Study

Heinrich-Heine University, Duesseldorf2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2003年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
100
试验地点
2
主要终点
difference in mean weight gain

研究概览

简要总结

The study is a prospective, randomized, open-label study.

详细描述

The principal objective of this trial is to investigate the effect of a comprehensive behavioural treatment program on weight gain in schizophrenic patients under olanzapine treatment, and on subjective well-being.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia
  • Ages between 18 and 65
  • Informed consent
  • Weight gain of at least 1.5 kg in the first 4 weeks
  • A sufficient understanding to participate adequately in the weight management program
  • Patients must agree to cooperate with all tests and examinations required by the protocol.
  • Each patient must understand the nature of the study and must sign an informed consent document.

排除标准

  • Serious, unstable somatic illnesses
  • Illnesses associated with weight gain including renal and endocrine diseases
  • Weight change greater than 3 kg in the preceding three months
  • Weight gain less than 1.5 kg in the first 4 weeks

结局指标

主要结局

difference in mean weight gain

时间窗: November 2007

次要结局

  • changes in waist circumference, blood pressure, blood lipids, fasting glucose(November 2007)

研究者

发起方
Heinrich-Heine University, Duesseldorf
申办方类型
Other

研究点 (2)

Loading locations...

相似试验

The Effect of a Weight Management Program During... | 临床试验